LPOXY initiates $28M Series A financing with 5 Horizons Ventures to fund pivotal trial
September 4, 2025 | Startland News Staff
PLATTE CITY, Mo. — Funding to secure the upcoming trial of a Missouri biopharmaceutical company’s solution for preventing a deadly gut infection could prove critical in the fight against a condition that claims 80 U.S. lives daily, said Dr. Larry Sutton.
LPOXY Therapeutics, which is developing a novel non-antibiotic therapy to prevent Clostridioides difficile infections (Cdiff), announced Wednesday it has signed a term sheet with 5Horizons Ventures, a life science venture capital firm focused on innovative healthcare solutions in support of a $28 million Series A financing.
Elevator pitch: LPOXY Therapeutics is transforming infection prevention with a first-in-class oral therapeutic aimed at preventing C. difficile colitis, a CDC-designated urgent public health threat that kills over 80 Americans every day. Our unique approach delivers oxygen directly to the gut, creating an environment hostile to C. difficile bacteria without using antibiotics.
The agreement facilitates the formation of an investment syndicate to fund LPOXY’s registrational STOP-Cdiff (SIDIPREV Trial On Prevention of C. difficile Infections) clinical trial.
“5 Horizons Ventures’ commitment marks a major milestone for LPOXY as we move toward launching our pivotal STOP-Cdiff trial,” said Sutton, CEO and co-founder of LPOXY, one of Startland News’ 10 Kansas City Startups to Watch in 2025. “SIDIPREV represents a novel approach to infection prevention that not only addresses a deadly unmet need but also aligns with hospital economics by reducing costly complications within fixed DRG payments.”
ICYMI: LPOXY Therapeutics punches back at gut infection (and a foe with a billion-year head start)
The upcoming trial is designed under the FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs guidance and is intended to serve as the registrational study for SIDIPREV™, a therapy that aims to prevent life-threatening Cdiff in high-risk hospitalized patients. C. difficile is categorized by the CDC as an urgent public health threat that kills 80 Americans every day.
SIDIPREV is an orally administered, enteric-coated capsule that releases a metered dose of oxygen into the lower gastrointestinal tract, creating an environment hostile to anaerobic pathogens like C. difficile. Oxygen also suppresses toxin production and has mucosal anti-inflammatory effects.
As planned, STOP-Cdiff is a randomized, placebo-controlled superiority trial that will evaluate the efficacy and safety of SIDIPREV in approximately 500 hospitalized patients at elevated risk for Cdiff due to age and antibiotic exposure. LPOXY aims to launch the trial in Q3 2026 and file for approval in 2029.
“We’re impressed by the LPOXY team, their data, and their clear-eyed strategy for succeeding where many anti-infective programs have struggled,” said Paul Ferguson, partner and CFO of 5 Horizons Ventures. “SIDIPREV avoids the reimbursement and resistance-related hurdles that have plagued traditional antibiotics, making this a rare opportunity to unlock real economic value for patients, hospitals, and investors.”
LPOXY is actively building its investment syndicate and is in discussions with other institutional investors aligned with its late-stage clinical strategy.
2025 Startups to Watch
stats here
Related Posts on Startland News
Pride outside: How the outdoor industry is missing out with a $1 trillion LGBTQ+ blind spot
“You can’t be what you can’t see,” said adventurer and speaker Mikah Meyer, quoting activist Marian Wright Edelman last week in Kansas City. Representation of LGBTQ+ consumers and entrepreneurs formed a thematic trail throughout the recent Mid-America Gay & Lesbian Chamber of Commerce awards luncheon where Meyer made keynote remarks. His borrowed quote also reflected…
nbkc launches Entrepreneur in Residence incubator: ‘I have a whole company behind me’
Less than a year after its inaugural Fountain City Fintech accelerator debuted, nbkc bank has launched a new incubator program designed to tackle common banking industry problems with start-up-style ideation, problem solving, and tenacity, said Megan Darnell. The goal: building new companies along the way, the nbkc program manager said. “Kansas City has every single…
Investors, students find potential and power in High School eSports League
Benjie Lewis saw potential in eSports from the beginning — first as a mentor, then an investor, he said. Rapidly evolving from recreational pastime to official leagues and high school sports programs, the competitive multiplayer gaming concept has created a new space for startup opportunity, he said. “When I was growing up … they weren’t…
Startup advocates to next mayor: Make KC more attractive to tech talent, women, innovation
Months of candidate forums are complete. The door bells have been rung. Selfies taken. As the Kansas City mayor’s race heads to the polls Tuesday, the candidates are all business when it comes to courting the startup community’s vote. Jolie Justus — who has branded herself as the next “neighborhood mayor” — and Quinton Lucas…